947 related articles for article (PubMed ID: 1446917)
1. Chemo-immunotherapy in patients with metastatic melanoma using sequential treatment with dacarbazine and recombinant human interleukin-2: evaluation of hematologic and immunologic parameters and correlation with clinical response.
Isacson R; Kedar E; Barak V; Gazit Z; Yurim O; Kalichman I; Ben-Bassat H; Biran S; Schlesinger M; Franks CR
Immunol Lett; 1992 Jul; 33(2):127-34. PubMed ID: 1446917
[TBL] [Abstract][Full Text] [Related]
2. Chemo-adoptive immunotherapy of nude mice implanted with human colorectal carcinoma and melanoma cell lines.
Gazit Z; Weiss DW; Shouval D; Yechezkeli M; Schirrmacher V; Notter M; Walter J; Kedar E
Cancer Immunol Immunother; 1992; 35(2):135-44. PubMed ID: 1596937
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of combined treatment with ch14.18 and R24 monoclonal antibodies and interleukin-2 for patients with melanoma or sarcoma.
Choi BS; Sondel PM; Hank JA; Schalch H; Gan J; King DM; Kendra K; Mahvi D; Lee LY; Kim K; Albertini MR
Cancer Immunol Immunother; 2006 Jul; 55(7):761-74. PubMed ID: 16187086
[TBL] [Abstract][Full Text] [Related]
4. Phenotypic and functional profile of peripheral blood mononuclear cells isolated from melanoma patients undergoing combined immunotherapy and chemotherapy.
Eisenthal A; Skornick Y; Ron I; Zakuth V; Chaitchik S
Cancer Immunol Immunother; 1993 Nov; 37(6):367-72. PubMed ID: 8242661
[TBL] [Abstract][Full Text] [Related]
5. Phase I/II study of sequential chemoimmunotherapy (SCIT) for metastatic melanoma: outpatient treatment with dacarbazine, granulocyte-macrophage colony-stimulating factor, low-dose interleukin-2, and interferon-alpha.
Groenewegen G; Bloem A; De Gast GC
Cancer Immunol Immunother; 2002 Dec; 51(11-12):630-6. PubMed ID: 12439608
[TBL] [Abstract][Full Text] [Related]
6. Recombinant interleukin-2 treatment in patients with metastatic colorectal cancer: effect on natural cytotoxicity.
Park KG; Heys SD; Murray JB; Hayes PD; Ashby JA; Franks CR; Eremin O
Cancer Immunol Immunother; 1992; 35(1):53-8. PubMed ID: 1611623
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy with intralesional and systemic interleukin-2 of patients with non-small-cell lung cancer.
Scudeletti M; Filaci G; Imro MA; Motta G; Di Gaetano M; Pierri I; Tongiani S; Indiveri F; Puppo F
Cancer Immunol Immunother; 1993 Jul; 37(2):119-24. PubMed ID: 8391391
[TBL] [Abstract][Full Text] [Related]
8. Immunological evaluation of patients with hematological malignancies receiving ambulatory cytokine-mediated immunotherapy with recombinant human interferon-alpha 2a and interleukin-2.
Morecki S; Revel-Vilk S; Nabet C; Pick M; Ackerstein A; Nagler A; Naparstek E; Ben Shahar M; Slavin S
Cancer Immunol Immunother; 1992; 35(6):401-11. PubMed ID: 1394343
[TBL] [Abstract][Full Text] [Related]
9. High-dose continuous venous infusion of interleukin-2: influence of dose and infusion rate on tumoricidal function and lymphocyte subsets.
Mertens WC; Banerjee D; al-Mutter N; Stitt L; Bramwell VH; Lala PK
Cancer Immunol Immunother; 1995 Nov; 41(5):271-9. PubMed ID: 8536272
[TBL] [Abstract][Full Text] [Related]
10. Activation of extracellular signaling regulated kinase in natural killer cells and monocytes following IL-2 stimulation in vitro and in patients undergoing IL-2 immunotherapy: analysis via dual parameter flow-cytometric assay.
Kondadasula SV; Varker KA; Lesinski GB; Benson DM; Lehman A; Olencki T; Monk JP; Kendra K; Carson WE
Cancer Immunol Immunother; 2008 Aug; 57(8):1137-49. PubMed ID: 18193422
[TBL] [Abstract][Full Text] [Related]
11. Adoptive immunotherapy with peripheral blood lymphocytes cocultured in vitro with autologous tumor cells and interleukin-2.
Sporn JR; Ergin MT; Robbins GR; Cable RG; Silver H; Mukherji B
Cancer Immunol Immunother; 1993 Aug; 37(3):175-80. PubMed ID: 8392912
[TBL] [Abstract][Full Text] [Related]
12. Serum levels of the low-affinity interleukin-2 receptor molecule (TAC) during IL-2 therapy reflect systemic lymphoid mass activation.
Voss SD; Hank JA; Nobis CA; Fisch P; Sosman JA; Sondel PM
Cancer Immunol Immunother; 1989; 29(4):261-9. PubMed ID: 2787694
[TBL] [Abstract][Full Text] [Related]
13. Clinical and immunological effects of human recombinant interleukin-2 given by repetitive weekly infusion to normal dogs.
Helfand SC; Soergel SA; MacWilliams PS; Hank JA; Sondel PM
Cancer Immunol Immunother; 1994 Aug; 39(2):84-92. PubMed ID: 8044833
[TBL] [Abstract][Full Text] [Related]
14. Significance of pericellular lacunae in cell blocks of effusions.
Price BA; Ehya H; Lee JH
Acta Cytol; 1992; 36(3):333-7. PubMed ID: 1580117
[TBL] [Abstract][Full Text] [Related]
15. Diffuse melanosis and trichochromuria in malignant melanoma.
Agrup G; Agrup P; Hansson C; Rorsman H; Rosengren E
Acta Derm Venereol; 1979; 59(5):456-7. PubMed ID: 93371
[TBL] [Abstract][Full Text] [Related]
16. Ablation of the brachial plexus. Control of intractable pain, due to a pathological fracture of the humerus.
Neill RS
Anaesthesia; 1979; 34(10):1024-7. PubMed ID: 539638
[TBL] [Abstract][Full Text] [Related]
17. Theophylline incorporation into the nucleic acids of theophylline-stimulated melanoma cells.
Steinberg ML; Whittaker JR
J Invest Dermatol; 1978 Oct; 71(4):250-6. PubMed ID: 212485
[TBL] [Abstract][Full Text] [Related]
18. Organ culture of mammalian skin and the effects of ultraviolet light and testosterone on melanocyte morphology and function.
Glimcher ME; Garcia RI; Szabó G
J Exp Zool; 1978 May; 204(2):229-37. PubMed ID: 641488
[TBL] [Abstract][Full Text] [Related]
19. [Ultrastructure of achromic malignant melanoma of the gingiva. value in differential diagnosis].
Dambrain R; Cordier A; Noel H
Rev Stomatol Chir Maxillofac; 1977; 78(8):519-27. PubMed ID: 276042
[TBL] [Abstract][Full Text] [Related]
20. Primary cutaneous malignant melanoma: experience of the British Columbia Cancer Agency from 1972 to 1981.
Carmichael VE; Wilson KS
Can J Surg; 1992 Dec; 35(6):589-97. PubMed ID: 1458384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
